Moberg pharma

Moberg pharma 6 month daily.

Sent ute i den här aktien som gått upp mycket och som nu har en hög värdering men ändå intressant att bevaka.

Redeye´s värdering:

Valuation

We value Moberg Pharma using a combination of multiples based on a peer group companies, and DCF. High dependency on the branded OTC nail fungus products and brief history as a profitable company imply greater risk compared to the more mature consumer health companies, and for this reason we use a WACC of 11.6 (12.4)%. However, if Moberg Pharma performs in line with our forecasts, we would expect to reduce the WACC over time. Based on our base case assumptions we derive a DCF value of SEK 80 (78). The multiple-based valuation, gives us a value of SEK 68 (66). Our fair value is based on an average of the two models and amounts to SEK 74 (72).